Highest-materiality recent filing
Nkarta Q1 net loss $27.8M ($0.37/shr); cash $266.7M; advances NKX019 trials
Cash, equivalents, and investments $266.7M as of Mar 31, 2026; expected to fund operations into 2029.
Nkarta enters into ATM equity offering agreement for up to $100 million
Sales Agreement with Stifel for at-the-market offering of up to $100M of common stock.
Nkarta reports FY2025 net loss of $104.1M; cash runway into 2029
Cash, equivalents and investments $295.1M at Dec 31, 2025; expected to fund operations into 2029.
Nkarta advances NKX019 into second dose cohort; cash runway into 2029
Enrollment in second dose-escalation cohort of NKX019 for autoimmune diseases is underway.
Nkarta Q1 net loss $32M; restructures 34% workforce; NKX019 autoimmune data due H2 2025
Q1 2025 net loss $32M ($0.43/share); cash, equivalents & securities $351.9M.
Nkarta cuts workforce 34%, CFO departs; NKX019 autoimmune data due H2 2025; cash into 2029
Workforce reduction of 34% (53 positions) to cut costs and extend cash runway into 2029.
Nkarta Q3 net loss $28.3M; cash $405.3M; drops NHL, focuses NKX019 on autoimmune
Net loss of $28.3M ($0.39 per basic/diluted share) for Q3 2024; cash, equivalents, investments $405.3M.
Nkarta Q2 net loss $25M; cash $426.7M; NKX019 autoimmune trial Ntrust-2 to start by year-end
Net loss of $25.0M ($0.34 diluted EPS); R&D expense $23.1M, G&A $7.6M.
Nkarta initiates Ntrust-1 in lupus nephritis, IND cleared for 3 more autoimmune indications
First patient in screening for Ntrust-1, a trial of NKX019 in refractory lupus nephritis.
Nkarta shareholders approve doubling authorized shares; elects Dr. Vratsanos to board
Shareholders approved increasing authorized common shares from 100M to 200M.
Nkarta Q1 net loss $29.5M; cash $450M; NKX019 lupus dosing on track
Cash, equivalents and investments of $450.0M at March 31, 2024, including $240.1M from March offering.
Nkarta raises ~$225.2M in underwritten offering of stock and pre-funded warrants
Offering of 21,010,000 shares at $10.00 and pre-funded warrants for 3,000,031 shares at $9.9999.
Nkarta shares NKX019 B-cell reconstitution and PK data from Phase 1 NHL trial
After NKX019 treatment, circulating CD19+ cells rapidly depleted; B-cell repertoire recovered with naïve, non-class-switched isotypes in 5 patients at 3 months.
Nkarta reports FY2023 net loss $117.5M; deprioritizes NKX101, advances NKX019 in autoimmune
FY2023 net loss of $117.5M ($2.40 per basic/diluted share).
Nkarta reports Q3 net loss $25.6M; cash $278.4M; extends runway into 2026
Net loss of $25.6M ($0.52 per share) for Q3 2023; R&D expenses $22.2M, G&A $7.1M.
Nkarta gets FDA IND clearance for NKX019 in LN; cuts workforce 10%, extends cash runway
FDA cleared IND for NKX019 (CAR NK) for lupus nephritis; enrollment starts H1 2024; up to 12 patients.
Nkarta Q2 net loss $33.3M ($0.68/share); cash $302.2M; NKX101 shows 67% CR/CRi with Flu/Ara-C
Cash and investments $302.2M as of June 30, 2023; cash runway into 2025.
Nkarta appoints Alyssa Levin as CFO and Business Officer effective July 1
Annual base salary of $450k, sign-on bonus of $20k, and a stock option for 442,400 shares.
Nkarta NKX101 achieves 67% CR/CRi in AML Phase 1 with modified lymphodepletion
In Flu/Ara-C cohort (n=6), NKX101 showed 67% CR/CRi rate (4/6) and 50% CR rate (3/6); 2 CRs MRD-negative.
Nkarta CFO Nadir Mahmood resigns effective June 30, 2023; clinical timelines reaffirmed
CFO Nadir Mahmood resigns to become CEO of a private biotech; effective June 30, 2023.
Nkarta reports FY2022 net loss of $113.8M; cash $354.9M; NKX101/019 updates in 2023
Net loss of $113.8M ($2.61 diluted EPS) for FY2022; Q4 loss $32.6M ($0.67).
Nkarta promotes David R. Shook, M.D., to Chief Medical Officer
Dr. Shook joined Nkarta in 2020 and was appointed VP, Clinical Development in 2022.
Nkarta: 70% CR at higher NKX019 doses in NHL; no neurotoxicity observed
7 of 10 NHL patients at 1B and 1.5B cell doses achieved complete response (70% CR, 80% ORR) across histologies including LBCL.
Nkarta announces Dec 5 call to review updated NKX019 clinical data; no data in filing
Conference call scheduled for December 5, 2022 at 8:00 a.m. ET to review updated clinical data from NKX019.
Nkarta Q3 2022 net loss $28.3M; cash $395.1M; NKX019 dose expansion opened
Net loss of $28.3M ($0.58 per share); R&D expense $23.4M, G&A $6.8M.
Nkarta Q2 net loss $27M; NKX101 AML 60% CR, NKX019 NHL 50% CR
Q2 2022 net loss $27.0M ($0.61/share); cash & investments $415.0M, sufficient into 2025.
Nkarta CMO Kanya Rajangam resigns; David Shook named VP Clinical Development
Dr. Kanya Rajangam resigns as CMO effective June 5, 2022, to oversee R&D at a private biotech.
Nkarta reports Q1 net loss $26.0M; shares positive AML/NHL clinical data
Net loss $26.0M ($0.79/share); cash, equivalents & short-term investments $219.1M at 3/31/22, plus $215.5M net from April offering, pro forma >$400M.
Nkarta completes $215.5M public offering of 15.3M shares at $15/sh
Sold 13.33M firm shares plus 2M option shares at $15.00/sh.
Nkarta reports 60% CR for NKX101 in AML; 83% ORR for NKX019 in NHL
NKX101: 3/5 AML patients at 1B/1.5B cells x3 achieved CR (60%); 2 of 3 CRs are MRD negative.
Nkarta reports full year 2021 net loss of $86.1M; NKX101 data expected 1H 2022
Full year 2021 net loss $86.1M ($2.62/share); Q4 net loss $22.8M ($0.69/share).
Nkarta reports Q3 net loss of $22.4M; NKX101 data pushed to 1H 2022
Net loss of $22.4M ($0.68 per share); R&D expense $16.6M, G&A $5.8M.
David Shook, M.D. notified Nkarta, Inc. (the “Company”) of his decision to resign as Chief Medical Officer and Head of Research & Development of the Company to pursue other opportunities in the oncology space.
Shawn Rose, M.D. Ph.D. has been appointed by the Company to succeed Dr. Shook as Chief Medical Officer and Head of Research and Development starting on June 23, 2025.
Effective as of Levin Transition Date, the Board appointed Nadir Mahmood, Ph.D., the Company’s President, to succeed Ms. Levin as the Company’s principal financial officer and principal accounting officer.
On March 26, 2025, the Company announced that Alyssa Levin’s employment would be terminated effective March 31, 2025
On July 10, 2024, Nkarta, Inc.'s (the “Company”) Board of Directors (the “Board”) appointed Nadir Mahmood, Ph.D. as the Company’s President, effective July 29, 2024.
On June 29, 2023, Nkarta, Inc.'s (the “Company”) Board of Directors (the “Board”) appointed Alyssa Levin as the Company’s Chief Financial and Business Officer and the principal financial and accounting officer, effective July 1, 2023.
Dr. Nadir Mahmood notified Nkarta, Inc. (the “Company”) of his decision to resign as Chief Financial and Business Officer of the Company to take a position as chief executive officer of a private biotechnology company.
On May 16, 2022, the Company issued a press release announcing the resignation of Dr. Rajangam and the appointment of Dr. David Shook as Vice President, Clinical Development.
On May 13, 2022, Dr. Kanya Rajangam notified Nkarta, Inc. (the “Company”) of her decision to resign as Chief Medical Officer of the Company to oversee research and development activities at a private biotechnology company.
On March 28, 2022, the Board of Directors (the "Board") of Nkarta, Inc. (the "Company"), on the recommendation of the Nominating and Governance Committee of the Board, increased the size of the Board from nine directors to ten directors and appointed Angela Thedinga to the Board effective immediately.
Max materiality 0.90 · Median 0.60 · Most common event other_material